Summary
Bone is one of the most common organs for solid tumour metastasis. 75% of patients with late-stage breast cancer develop recurrence in bone. Current treatments are palliative, leaving this condition incurable, with an unmet need to identify new therapies. Inflammation is an important player in cancer. My pilot data show that depletion of a specific immune cell type, neutrophils, impairs bone metastasis in vivo, suggesting that neutrophils have tumour-supporting functions. However, the role of neutrophils in the metastatic bone niche remains largely unexplored, it is unknown whether they contribute to the seeding or the expansion phase of bone metastasis and if tumour cells regulate neutrophil plasticity, therefore skewing the balance towards pro-tumourigenic neutrophil subsets. I hypothesise that neutrophils acquire pro-tumourigenic phenotypes when in close proximity to cancer cells and support metastatic progression by regulating the tumour niche. By using a liposoluble fluorescent protein expressed by cancer cells, neighbouring neutrophils will be characterised: Neutrophil subsets will be identified by spectral cytometry, their transcriptomic signature analysed using RNA sequencing and their pro-tumourigenic role functionally assessed in vitro and in vivo. By employing a combination of MALDI-MSI and multiplex antibody-based imaging, neutrophil-cancer cell interactome will be established in order to identify candidate molecular mechanisms regulating neutrophil pro-tumourigenic functions. By using in vivo models of neutrophil extracellular traps (NETs) blockade, neutropenia, neutrophilia and enhanced neutrophil retention in the bone marrow, neutrophil candidate mechanisms shaping the metastatic niche will be determined. Dissecting the molecular mechanisms regulating pro-tumourigenic neutrophil subsets is fundamental to identify novel means of inhibiting bone metastasis without affecting neutrophil critical functions in inflammation.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101065578 |
| Start date: | 01-07-2023 |
| End date: | 30-06-2025 |
| Total budget - Public funding: | - 173 847,00 Euro |
Cordis data
Original description
Bone is one of the most common organs for solid tumour metastasis. 75% of patients with late-stage breast cancer develop recurrence in bone. Current treatments are palliative, leaving this condition incurable, with an unmet need to identify new therapies. Inflammation is an important player in cancer. My pilot data show that depletion of a specific immune cell type, neutrophils, impairs bone metastasis in vivo, suggesting that neutrophils have tumour-supporting functions. However, the role of neutrophils in the metastatic bone niche remains largely unexplored, it is unknown whether they contribute to the seeding or the expansion phase of bone metastasis and if tumour cells regulate neutrophil plasticity, therefore skewing the balance towards pro-tumourigenic neutrophil subsets. I hypothesise that neutrophils acquire pro-tumourigenic phenotypes when in close proximity to cancer cells and support metastatic progression by regulating the tumour niche. By using a liposoluble fluorescent protein expressed by cancer cells, neighbouring neutrophils will be characterised: Neutrophil subsets will be identified by spectral cytometry, their transcriptomic signature analysed using RNA sequencing and their pro-tumourigenic role functionally assessed in vitro and in vivo. By employing a combination of MALDI-MSI and multiplex antibody-based imaging, neutrophil-cancer cell interactome will be established in order to identify candidate molecular mechanisms regulating neutrophil pro-tumourigenic functions. By using in vivo models of neutrophil extracellular traps (NETs) blockade, neutropenia, neutrophilia and enhanced neutrophil retention in the bone marrow, neutrophil candidate mechanisms shaping the metastatic niche will be determined. Dissecting the molecular mechanisms regulating pro-tumourigenic neutrophil subsets is fundamental to identify novel means of inhibiting bone metastasis without affecting neutrophil critical functions in inflammation.Status
SIGNEDCall topic
HORIZON-MSCA-2021-PF-01-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Search
